Skip Navigation

Phase I/II Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells VCAR33 in Patients with Relapsed or Refractory Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT05984199

Study #:
STUDY00150673

Start Date:
Jan 26, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05984199

View Complete Trial Details & Eligibility at ClinicalTrials.gov